Nephrology Lab · DeCure for X
DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for urethral syndrome — screening already-approved drugs against its 36-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for urethral syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Janus kinase 1 (JAK1) — JAK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 6BBU · 2.08 Å · ligand N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (D7D). Experimental structure, not a prediction.
In 40 patients treated with the Richardson urethroplasty, 38 reported improvement in clinical symptoms and urine flow rate; two patients relapsed but improved after further surgery. A separate 1976 study described submucosal injection of triamcinolone acetonide around Skene’s glands as a new office-based treatment for urethral syndrome, claiming it decreased inflammation and scarring while all other modalities were surgical. No response rates or sample sizes beyond the procedure description were given for that corticosteroid injection.
A 1984 study of 40 women with urethral syndrome and 46 women with conventional urinary tract infection found that general practitioners could distinguish the two conditions before urine culture results arrived. Patients with urethral syndrome had appreciably less dysuria than those with infection, but appreciably more psychological illness. The authors concluded this ability to distinguish had clinical and economic implications.
A 2016 review stated that urethral syndrome is a diagnosis of exclusion with diverse possible causes: infections, paraurethral gland inflammation, sphincter or pelvic floor muscle spasms, oestrogen deficiency, trauma, neuropathies, hypersensitivity, and psychosomatic issues. It emphasised that patients must be evaluated and treated holistically, require considerable time and attention, and that psychosocial aspects may have a crucial impact on disease course. No controlled trials comparing any drug against placebo or standard care were identified in these abstracts. What remains missing is any randomised trial with adequate sample size, a validated patient stratification method, and funding to test specific pharmacological interventions against sham or conservative management.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractThe technique of urethroplasty described by Richardson has been used to treat 40 patients with the urethral syndrome. 38 patients have had improvement in clinical symptoms and urine flow rate following this procedure. 2 patients have had a relapse of symptoms but both have been improved by further surgery.
https://doi.org/10.1111/j.1464-410x.1977.tb04095.xAbstractIn a study of 40 women with the urethral syndrome and 46 women with conventional urinary tract infection, none of whom was pregnant, general practitioners predicted the diagnosis correctly before the report on the midstream urine specimen was received, as evidenced by their management. They seemed to do this by balancing the symptom of dysuria with the psychological make up of the patient: patients with the urethral syndrome suffered appreciably less dysuria than patients with urinary tract infection; patients with the urethral syndrome suffered appreciably more psychological illness. This ability to distinguish between the two disorders has important clinical and economic implications.
https://doi.org/10.1136/bmj.288.6427.1347AbstractA new method for the treatment of the urethral syndrome is presented. Therapy involves the submucosal injection of triamcinolone acetonide around Skene's glands to decrease inflammation and scarring. It is a simple office procedure, while all other therapeutic modalities are surgical.
https://doi.org/10.1016/s0022-5347(17)58919-3AbstractThe urethral syndrome with urethral pain and bladder voiding disorders is a diagnosis of exclusion. Possible aetiologies are diverse and include organic, functional and inflammatory pathologies of the urethra. Infections, inflammation of the paraurethral glands, spasms of the sphincter muscle and/or of the pelvic floor muscles, oestrogen deficiency, trauma, neuropathies, hypersensitivity and psychosomatic issues have been investigated as possible causes.Patients with urethral syndrome must be viewed, evaluated and treated holistically. They need a lot of time and attention during their evaluation and treatment. It is now well known that psychosocial aspects are involved in the development of many somatic conditions and may have a crucial impact on the course of a disease. This needs to be taken into consideration during the treatment process.
https://doi.org/10.1055/s-0042-106662Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
